Previous 10 | Next 10 |
Topical psoriasis treatments account for 42% of the $11.37 billion psoriasis drug market Topline results from Phase III oral Piclidenoson study expected Q2 2022 Piclidenoson has been out-licensed for the systemic indication of psoriasis in certain major mar...
Phase III psoriasis topline data for Can-Fite’s lead drug candidate Piclidenoson expected Q2 2022 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflamm...
Can-Fite Biopharma press release (NYSE:CANF): FY GAAP EPS of -$0.03. Revenue of $0.85M (+11.8% Y/Y). On December 31, 2021, the company had $18.9 million in cash, cash equivalents, and short-term deposits For further details see: Can-Fite Biopharma GAAP EPS of -$0.03, revenue of $0.85M ...
Cash balance of $18.9 million as of December 31, 2021 Signed out-licensing deal worth $42.7 million with Ewopharma Phase III psoriasis topline data expected Q2 2022 Namodenoson induced complete response and cleared all cancer lesions in ...
Can-Fite BioPharma (NYSE:CANF) said it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) related to its drug Namodenoson (CL-IB-MECA) to treat liver fibrosis. The company said its invention is titled “Method for Treating Fibrotic Liver Tissue Usin...
Broad patent addresses markets for the treatment of all advanced liver fibrosis indications Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer...
Can-Fite will conduct 1x1 meetings with companies in the cannabis field regarding potential collaboration Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflam...
Gainers: Voyager Therapeutics (NASDAQ:VYGR) +22%. 908 Devices (NASDAQ:MASS) +16%. Viemed Healthcare (NASDAQ:VMD) +10%. Cara Therapeutics (NASDAQ:CARA) +9%. Neuronetics (NASDAQ:STIM) +9%. Losers: Alector (NASDAQ:ALEC) -19%. Can-Fite BioPharma (NYSE:CANF)...
Digital Brands Group (NASDAQ:DBGI) -19%. Imperial Petroleum (NASDAQ:IMPP) -18%. New Concept Energy (NYSE:GBR) -11%. Indonesia Energy Corporation (NYSE:INDO) -10%. Frontline (NYSE:FRO) -9%. Borr Drilling (NYSE:BORR) -9%. Houston American Energy (NYSE:HUSA) -9%. Sibanye Stillwater (NYSE:SBSW)...
Can-Fite BioPharma (NYSE:CANF), a clinical-stage biopharmaceutical company, is trading ~3% lower in the pre-market Tuesday after announcing a delay for a key data readout for the company’s lead candidate Piclidenoson from a late-stage trial in psoriasis. Piclidenoson, an oral...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...